Drugs-related Death Rates Soon After Hospital-discharge for Ever-IDU Behavioral Risk-factor, SDMD Cohort, Scotland, 1996–2010.

<p>Drugs-related Death Rates Soon After Hospital-discharge for Ever-IDU Behavioral Risk-factor, SDMD Cohort, Scotland, 1996–2010.</p

Drugs-related Death Rates Soon After Hospital-discharge Within 28 and 90 Days After Hospital-discharge by Duration of Hospital-stay and Main Discharge-diagnosis Versus Ever-IDU and Reported Misuse of Alcohol, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval; IDU, Injecting Drug User</p><p>^a All diagnoses not included in specified groups</p><p>^b Diagnoses related to drug misuse, (a) Poisonings by drugs, medicaments & biological substances and (b) Mental & behavioral disorders due to psychoactive substance</p><p>^c All mental and behavioral disorders, excluding those due to psychoactive substances</p><p>Drugs-related Death Rates Soon After Hospital-discharge Within 28 and 90 Days After Hospital-discharge by Duration of Hospital-stay and Main Discharge-diagnosis Versus Ever-IDU and Reported Misuse of Alcohol, SDMD Cohort, Scotland, 1996–2010.</p

Descriptive Statistics for characteristics at First SDMD Registration by Registration Era, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: SDMD, Scottish Drugs Misuse Database</p><p>Descriptive Statistics for characteristics at First SDMD Registration by Registration Era, SDMD Cohort, Scotland, 1996–2010.</p

Drugs-related Death Rates Soon After Hospital-discharge for Reported Misuse of Alcohol Behavioral Risk-factor, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval; IDU, Injecting Drug User</p><p>Drugs-related Death Rates Soon After Hospital-discharge for Reported Misuse of Alcohol Behavioral Risk-factor, SDMD Cohort, Scotland, 1996–2010.</p

Descriptive Statistics for outcomes by Follow-up Era, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database</p><p>^a Excluding DRD suicides which are included in the DRD total,</p><p>^b Restricted to individuals with first SDMD registration in 2006–2010 as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141073#pone.0141073.t001" target="_blank">Table 1(a)</a></p><p>Descriptive Statistics for outcomes by Follow-up Era, SDMD Cohort, Scotland, 1996–2010.</p

Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Adjusted Using Cox Proportional Hazards Regression With Calendar Time as the Underlying Time-scale, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: SDMD, Scottish Drugs Misuse Database; CI, Confidence Interval</p><p>Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Adjusted Using Cox Proportional Hazards Regression With Calendar Time as the Underlying Time-scale, SDMD Cohort, Scotland, 1996–2010.</p

Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Unadjusted, SDMD Cohort, Scotland, 1996–2010.

<p>Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval</p><p>Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Unadjusted, SDMD Cohort, Scotland, 1996–2010.</p

Individual-level analyses: unweighted and weighted models of the association between self-reported uptake of harm reduction interventions and recent HCV infection^a.

<p>(A)OR =  (adjusted) odds ratio; CI =  confidence interval; OST =  opiate substitution therapy; N/S =  needle/syringe; para  =  paraphernalia.</p>a<p>Where a recent infection is defined as anti-HCV negative and HCV-RNA positive.</p>b<p>All models adjusted for survey year, homelessness in last 6 months, stimulant injection in last 6 months, time since onset of injecting.</p>c<p>Restricted to those who reported injecting in the last 6 months; see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0104515#s2" target="_blank">methods</a> for definition of high and low coverage.</p>d<p>Paraphernalia refers to spoons and filters.</p>e<p>Where ‘no OST/OST’ refers to no current/current receipt of OST, ‘low’ refers to low coverage, and ‘high’ refers to high coverage.</p

Summary of evidence for the analytical framework.

<p>(A)OR =  (adjusted) odds ratio; N/S =  needles/syringes; OST =  opiate substitution therapy; PWID =  people who inject drugs.</p>a<p>Note that this study found an AOR for sharing needles/syringes (+/− paraphernalia) of 6.7 (95% CI 2.6–17.1) and an AOR for sharing paraphernalia only of 3.0 (95% CI 1.2–7.5). It was not possible to separate the effects of needles/syringes due to few individuals who reported sharing only needles/syringes. It is, however, assumed that the potential AOR for needles/syringes could be even higher than that detected for needles/syringes +/− paraphernalia.</p

Prevalence (among recent onset injectors) and derived incidence of HCV among people who inject drugs in Scotland, 2008 to 2012.

<p>The diamonds/circles represent the point estimate and the bars represent the upper and lower 95% confidence intervals. ^aanti-HCV prevalence among those who commenced injecting within the past 12 months. ^bDetermined by applying the estimated pre-seroconversion window period to the observed number of anti-HCV negative and HCV-RNA positive individuals (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0104515#s2" target="_blank">methods</a> for details). Restricted to those who had injected in the last 6 months.</p